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Statins for Secondary Prevention in Elderly Patients
A Hierarchical Bayesian Meta-Analysis
Jonathan Afilalo, MD,* Gustavo Duque, MD, PHD,*† Russell Steele, PHD,‡
J. Wouter Jukema, MD, PHD,§ Anton J. M. de Craen, PHD, Mark J. Eisenberg, MD, MPH*¶
Montreal, Canada; and Leiden, the Netherlands
Objectives This study was designed to determine whether statins reduce all-cause mortality in elderly patients with coro-
nary heart disease.
Background Statins continue to be underutilized in elderly patients because evidence has not consistently shown that they
reduce mortality.
Methods We searched 5 electronic databases, the Internet, and conference proceedings to identify relevant trials. In addi-
tion, we obtained unpublished data for the elderly patient subgroups from 4 trials and for the secondary preven-
tion subgroup from the PROSPER (PROspective Study of Pravastatin in the Elderly at Risk) trial. Inclusion criteria
were randomized allocation to statin or placebo, documented coronary heart disease, 50 elderly patients (de-
fined as age 65 years), and 6 months of follow-up. Data were analyzed with hierarchical Bayesian modeling.
Results We included 9 trials encompassing 19,569 patients with an age range of 65 to 82 years. Pooled rates of all-
cause mortality were 15.6% with statins and 18.7% with placebo. We estimated a relative risk reduction of 22%
over 5 years (relative risk [RR] 0.78; 95% credible interval [CI] 0.65 to 0.89). Furthermore, statins reduced coro-
nary heart disease mortality by 30% (RR 0.70; 95% CI 0.53 to 0.83), nonfatal myocardial infarction by 26% (RR
0.74; 95% CI 0.60 to 0.89), need for revascularization by 30% (RR 0.70; 95% CI 0.53 to 0.83), and stroke by
25% (RR 0.75; 95% CI 0.56 to 0.94). The posterior median estimate of the number needed to treat to save 1
life was 28 (95% CI 15 to 56).
Conclusions Statins reduce all-cause mortality in elderly patients and the magnitude of this effect is substantially larger than
had been previously estimated. (J Am Coll Cardiol 2008;51:37–45) © 2008 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.063m
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loronary heart disease (CHD) is the leading cause of death
mong elderly patients, with 80% of coronary deaths
ccurring in patients over the age of 65 (1). Despite the
See page 46
ecommendation of the third National Cholesterol Educa-
ion Program Adult Treatment Panel to intensively lower
ipids in elderly patients with CHD (2–4), statin utilization
ontinues to be 40% to 60% in elderly patients after
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ccepted June 25, 2007.yocardial infarction (MI) (5–8). Utilization is suboptimal
ecause evidence has not consistently shown that statins
educe mortality in elderly patients (9–13). Thus, the
rimary objective of this meta-analysis was to determine
hether statins reduce all-cause mortality in elderly patients
ith CHD and to quantify the magnitude of the treatment
ffect. The secondary objective was to determine whether
tatins reduce CHD mortality, nonfatal MI, need for
evascularization, and stroke.
ethods
e carried out this meta-analysis in accordance with
tandards set forth by the Quality of Reporting of Meta-
nalyses of Randomised Controlled Trials (QUOROM)
tatement (14).
earching. We searched Ovid MEDLINE from 1966 to
ecember 2007 with the following search terms:
ydroxymethylglutaryl-CoA reductase inhibitors, anticho-
esteremic agents, “fluvastatin,” “pravastatin,” “simvastatin,”
atorvastatin,” “rosuvastatin,” “lovastatin,” “cerivastatin,”
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Statins for Secondary Prevention in Elderly Patients January 1/8, 2008:37–45randomized controlled trials
(RCT), clinical trials, “random-
ized,” myocardial infarction, and
coronary disease. We searched
EMBASE from 1980 to Decem-
ber 2007, the Cochrane Central
Register of Controlled Trials and
Database of Abstracts of Reviews
of Effects from inception to the
fourth quarter of 2007, and the
ACP Journal Club from 1991 to
November/December 2007. We
also searched the Internet and
abstracts from major cardiology
conferences in North America
nd Europe. We used relevant references from retrieved
ublications and PubMed’s related articles feature to iden-
ify studies not captured by our primary search strategy.
inally, we contacted investigators by telephone and e-mail
o obtain unpublished data for elderly subgroups. We
imited our search to human studies in any language.
election. The inclusion criteria for our meta-analysis
ere: 1) randomized allocation to statin or placebo;
) documented CHD at the time of randomization; 3) at least
0 elderly patients included in the study (defined as age 65
ears); 4) at least 6 months of follow-up; and 5) all-cause
ortality, CHD mortality, nonfatal MI, need for revascu-
arization, or stroke reported as an outcome measure. Three
eviewers (J.A., M.J.E., G.D.) screened retrieved studies
nd determined whether these selection criteria were met.
alidity assessment. All qualifying studies were assessed
or concealment of randomized assignment, completeness of
ollow-up, and intention-to-treat analysis. We recorded
hether patients in the intervention and control groups
ere similar at the start of the study and treated equally
xcept for the designated treatment. We also recorded
hether patients in the control group were taking lipid-
owering drugs during the study. Variables reflecting inter-
al validity and study quality are shown in Table 1.
ata abstraction. All data were extracted in duplicate by 2
nvestigators (J.A., M.J.E.) using a standardized protocol
nd reporting form and independently verified by 1 inves-
igator (G.D.). Disagreements were resolved by consensus.
e collected information on name of study, year of recruit-
ent and publication, number of patients, duration of
ollow-up, inclusion and exclusion criteria, age, gender,
rior MI or revascularization, coronary risk factors, medi-
ations, baseline lipid levels, change in lipid levels, interven-
ion drug and dose, and nature of control. The outcome
easures abstracted were all-cause mortality, CHD mortal-
ty, nonfatal MI, need for revascularization defined as
ercutaneous coronary intervention or aortocoronary bypass
urgery, and stroke. We were able to extract overall study
ata. We did not obtain individual patient data.
tudy characteristics. Differences in study and patient
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  credible interval
MI  myocardial infarction
QUOROM  Quality of
Reporting of Meta-Analyses
of Randomised Controlled
Trials
RCT  randomized
controlled trial
RR  relative riskharacteristics introduced an additional source of heteroge- feity in the estimated treatment effects between trials.
hese differences would not be adequately dealt with in a
xed-effects meta-analysis model that uses only variability
temming from differences in sample sizes. Moreover,
ifferences in length of follow-up would not be dealt with in
random-effects meta-analysis model. We therefore em-
loyed a Bayesian hierarchical model to account for all of
hese between-trial variations.
uantitative data synthesis. In our Bayesian hierarchical
odel, the probability of an event within each group of each
rial was allowed to vary both between the treatment and
ontrol groups within each study and between each study
ncluded in the meta-analysis. We modeled the baseline log
dds of an event as normal random variables drawn from a
ommon normal distribution, with the mean equal to the
aseline log odds in the population of possible studies and
ariance representing the variability across studies. We
imilarly modeled the changes in log odds of an event
ttributable to treatment as normal random variables drawn
rom a common normal distribution, with the mean equal to
he population effect of the treatment on the log odds and
ariance representing the variability in treatment effect
cross studies.
A fully Bayesian data analysis requires us to specify our
rior beliefs about the population-level parameters. We
sed normal (mean  0, variance  1,000) prior distribu-
ions for all population means and regression coefficients
nd loosely informative inverse chi-square prior distribu-
ions for all variances to allow the data, rather than the prior
istributions, to have a stronger influence on the results.
eparate sensitivity analyses (not shown here) conducted
ith various uniform and inverse-gamma priors for the
ariances were found to have some effect on the estimates.
nferences were calculated with the Gibbs sampler pro-
rammed in WinBUGS software (version 1.4, MRC Bio-
tatistics Unit, Cambridge, United Kingdom) using 3 chains
nd 100,000 samples per chain. Finally, we included forest
lots for all major outcomes, which display the relative risks
RR) and 95% credible intervals (CI) for the individual
CTs and for the pooled results from our meta-analysis
ssuming a follow-up of 5 years.
esults
rial flow. The QUOROM flow diagram is shown in
igure 1. Our search identified 729 studies, of which 66
ere relevant based on their title and abstract and 16 met
redetermined selection criteria. In the PROSPER (PRO-
pective Study of Pravastatin in the Elderly at Risk) trial, the
nly RCT restricted to elderly patients, primary and sec-
ndary prevention cohorts had been enrolled (10). We were
ble to obtain previously unpublished data for the secondary
revention cohort and incorporate them into our meta-
nalysis. We contacted investigators from each of the
tudies by telephone and e-mail to obtain unpublished data
or their respective elderly patient subgroups (because 11 of
Trial Characteristics
Table 1 Trial Characteristics
Published Elderly Subgroups Unpublished Elderly Subgroups
4S CARE LIPID HPS PLAC I REGRESS FLARE LIPS PROSPER
Year 1997 1998 2001 2002 1995 1995 1999 2002 2002
Mean follow-up, yrs 5.4* 5.0* 6.1 5.0 2.3 2.0 0.8 3.9* 3.2
No. of elderly 1,021 1,283 3,514 10,697 94 138 366 623 1,833
Age range, yrs 65–70 65–75 65–75 65–80 65–75 65–70 65–80 65–80 70–82
Mean age, yrs (SD) 66.8 (1.4) 69.0 (66,73)* 68.8 (2.7) n/a 68.3 (2.6) 67.6 (1.5) 70.4 (3.7) 70.1 (3.9) 75.6 (3.4)
Inclusion criteria MI 6 months or
stable angina
MI 3–20 months MI or unstable angina
3–36 months
Vascular disease
or diabetes
Angiographic CAD
or recent MI
Angiographic CAD CAD requiring
PCI
CAD requiring
PCI
MI 6 months or
stable angina
Study drug
Drug Simvastatin Pravastatin Pravastatin Simvastatin Pravastatin Pravastatin Fluvastatin Fluvastatin Pravastatin
Dose, mg/day 20-40 40 40 40 40 40 80 80 40
Nonstudy drugs
Aspirin, % 35 82 79 63† 65 49 68 96 63
Beta-blockers, % 54 37 45 26† 18 74 57 54 33
Baseline characteristics
Women, % 24 18 20 25† 39 0 23 22 42
Diabetes, % 5 19 10 29† 0 0 9 15 9
Smoking, % 18 12 6 14† 17 n/a 16 15 16
Hypertension, % 29 48 45 41† 57 27 38 43 46
Prior MI, % 83 100 60 41† 38 49 26 42 42
Mean baseline lipid levels, mmol/l§
Total cholesterol 6.7 5.4 5.6 5.9† 6.0 5.8 5.5 5.1 5.7
LDL-C 4.9 3.6 3.9 3.4† 4.2 4.1 3.8 3.4 3.8
HDL-C 1.2 1.0 0.9 1.1† 1.1 0.9 1.1 1.0 1.2
Triglycerides 1.5 1.7 1.5 2.1† 1.9 1.6 1.5 1.6 1.6
Mean change in lipid levels, %
Total cholesterol 26 20 19 20† 19 19 23 17 n/a
LDL-C 36 29 28 29† 28 27 32 24 32‡
HDL-C 7 4 7 3† 8 9 4 1 5‡
Triglycerides 14 12 11 14† 10 13 5 2 12‡
Study quality
Follow-up, % 100 99 99 99 78 99 95 99 89‡
Intention-to-treat Yes Yes Yes Yes Yes n/a Yes Yes Yes
Double-blind Yes Yes Yes Yes Yes Yes Yes Yes Yes
*Median (Q1, Q3). †Data from the published cohort of young and elderly patients. ‡Data from the published cohort of primary and secondary prevention patients. §To convert total cholesterol, LDL-C, and HDL-C frommmol/l to mg/dl, divide by 0.02586. To convert triglycerides
from mmol/l to mg/dl, divide by 0.01129.
CAD  coronary artery disease; MI  myocardial infarction; LDL-C  low-density-lipoprotein cholesterol; HDL-C  high-density-lipoprotein cholesterol; n/a  not available; MI  myocardial infarction; PCI  percutaneous coronary intervention.
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Statins for Secondary Prevention in Elderly Patients January 1/8, 2008:37–45he 16 RCTs did not explicitly report results for this
ubgroup). In total, we obtained elderly patient data from 9
CTs: 4 from published sources (15–18) and 5 from
npublished sources (10,19–22). Unpublished data were
xtracted from the original RCT databases and provided in
riting by the investigators of the RCTs. The elderly
atient subgroup analysis from the CARE (Cholesterol
nd Recurrent Events) trial had been previously published
Figure 1 QUOROM Flow Diagram
CHD  coronary heart disease; MI  myocardial infarction; QUOROM 
Quality of Reporting of Meta-Analyses; RCT  randomized controlled trial.
Figure 2 Bayesian Forest Plot for All-Cause Mortality
Statin therapy reduced the incidence of all-cause mortality by 22% over 5 years
as compared to placebo. The posterior median estimate of the number need to treut did not report the all-cause mortality data. We were able
o obtain these data from the investigators, and they are
resented in Figure 2.
tudy characteristics. The trial characteristics are shown in
able 1. There were 9 RCTs: REGRESS (REgression
Rowth Evaluation Statin Study) (22), PLAC I (Pravastatin
imitation of Atherosclerosis in the Coronary arteries I)
19), 4S (Scandanavian Simvastatin Survival Study) (15,23),
ARE (16,24), FLARE (FLuvastatin Angiographic REste-
osis) (20), LIPID (Long-term Intervention with Pravasta-
in in Ischaemic Disease) (17,25), LIPS (Lescol Interven-
ion Prevention Study) (21), PROSPER (10), and HPS
Heart Protection Study) (18,26). These RCTs were pub-
ished between 1995 and 2002. The total number of elderly
atients was 19,569, and the mean weighted follow-up
eriod was 4.9 years (95,929 patient-years). In HPS, 35% of
atients were enrolled on the basis of noncoronary vascular
isease and 1% on the basis of high-risk hypertension. We
onducted analyses with and without this trial. Among
ontrol-group patients, the utilization of lipid-lowering
rugs varied between 2% and 24%, although analyses were
onducted on an intention-to-treat basis in 8 out of 9
CTs. The primary outcome measure was major adverse
ardiac events in 6 of 9 RCTs and angiographic progression
f coronary artery disease in FLARE, PLAC I, and
EGRESS.
uantitative data synthesis. Figures 2 to 6 show Bayesian
orest plots with the posterior relative risk estimates for each
tudy and the pooled relative risk estimates for 5 years of
ollow-up. The value of follow-up used for the pooled
stimates did not noticeably affect the results. We estimated
relative risk reduction of 22% for all-cause mortality (RR
.78; 95% CI 0.65 to 0.89). The posterior median estimate
f the number needed to treat to save 1 life was 28 (95% CI
5 to 56). Coronary heart disease mortality was reduced
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January 1/8, 2008:37–45 Statins for Secondary Prevention in Elderly Patientsy 30% (RR 0.70; 95% CI 0.53 to 0.83), with a number
eeded to treat of 34 (95% CI 18 to 69). Nonfatal MI was
educed by 26% (RR 0.74; 95% CI 0.60 to 0.89), with a
umber needed to treat of 38 (95% CI 16 to 118). Need
or revascularization was reduced by 30% (RR 0.70; 95%
I 0.53 to 0.83), with a number needed to treat of 24
95% CI 12 to 59). Stroke was reduced by 25% (RR 0.75;
5% CI 0.56 to 0.94), with a number needed to treat of
8 (95% CI 27 to 177).
ensitivity analysis. Standard convergence diagnostics
uch as those proposed by Gelman and Rubin (27,28) and
aftery and Lewis (29) showed that all 3 chains for the 4
utcomes converged quite quickly. We conducted a sub-
tantial sensitivity analysis to evaluate our choice of prior
istributions. Typically, Bayesian hierarchical model infer-
Figure 3 Bayesian Forest Plot for Coronary Heart Disease Mort
Statin therapy reduced the incidence of coronary heart disease mortality by 30%
over 5 years as compared to placebo. The posterior median estimate of the numb
Figure 4 Bayesian Forest Plot for Nonfatal Myocardial Infarctio
Statin therapy reduced the incidence of nonfatal myocardial infarction by 26%
over 5 years as compared to placebo. The posterior median estimate of the numbnces are most sensitive to the choice of prior distributions
or the variances of the baseline and treatment random
ffects. Owing to the small number of studies used in our
nalysis, we found that our results were sensitive to different
hoices of prior distribution for the variances. However, to
btain pooled relative risk intervals that contained 1.0 for
ny particular outcome, one would have to use prior
istributions that would imply strong a priori beliefs that
ariability between studies would be large.
We also experimented with a uniform prior over a wide
nterval and obtained similar results to those obtained with
he inverse chi-square priors. It should also be noted that
he magnitude of the treatment effect does increase as one
ncreases a prior variability; it is the precision of the interval
hat affects interpretation of the results. The proportion of
d to treat was 34.
d to treat was 38.ality
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Statins for Secondary Prevention in Elderly Patients January 1/8, 2008:37–45atients with prior MI had been identified as a potential
onfounder because of significant variability between trials
26% to 100%) and questionable treatment effects in low-
isk populations. We conducted Bayesian analyses adjusting
or the proportion of patients with prior MI (including
nalyses with and without the HPS trial) and found that the
reatment effects remained consistent. Finally, we conducted
nadjusted non-Bayesian Frequentist analyses and again
ound that the treatment effects remained consistent.
iscussion
n elderly patients with documented CHD, statins reduce
ll-cause mortality by 22%, CHD mortality by 30%, non-
atal MI by 26%, need for revascularization by 30%, and
troke by 25%. These estimates are rigorous and precise,
wing in large part to our Bayesian hierarchical model and
Figure 5 Bayesian Forest Plot for Revascularization
Statin therapy reduced the need for revascularization (percutaneous coronary inter
surgery) by 30% over 5 years as compared to placebo. The posterior median estim
Figure 6 Bayesian Forest Plot for Stroke
Statin therapy reduced the incidence of stroke by 25% over 5 years as comparedarger sample size of elderly patients, who had historically
een under-represented in clinical trials. Achieving a high
evel of precision was critical, because summary odds ratios
or all-cause mortality from 23 meta-analyses had been
ariable and heterogeneous (9). Contemporary meta-
nalyses suggested that the relative reduction in all-cause
ortality was similar in young and elderly patients, with a
odest number needed to treat of 56 to 61 and an upper
onfidence interval limit approaching 100 (30,31). Our
eta-analysis shows that the absolute benefit of statin
herapy was underestimated in the elderly patient popula-
ion, with a number needed to treat for all-cause mortality
f 28 and a narrower credible interval.
Our meta-analysis supports the value of statins in RCT
atients starting therapy at 65 to 82 years of age. Extrapo-
ation to older “real-world” patients is supported by obser-
n or aortocoronary bypass
the number need to treat was 24.
ebo. The posterior median estimate of the number need to treat was 58.ventio
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January 1/8, 2008:37–45 Statins for Secondary Prevention in Elderly Patientsational studies (32,33) and by statistical analysis of baseline
isk and number needed to treat (34). The largest observa-
ional study showed that statins reduced all-cause mortality
n patients with angiographically proven coronary artery
isease up to 97 years of age (32). One of the most
nteresting findings of this study was that older patients
ttained a greater reduction than younger patients; the
elative risk reduction for all-cause mortality was 50% in
atients aged 80 to 97, 44% in patients aged 65 to 79, and
0% in patients aged 65 years. Assuming a relative risk
eduction that is greater than or equal to younger patients,
he absolute risk reduction will be greater in the elderly
ecause it is a function of baseline risk. Elderly patients have
higher baseline risk of mortality; therefore, they have a
reater absolute risk reduction and a lower number needed
o treat (34).
Skepticism regarding the effects of statin therapy in
lderly patients surfaced after the PROSPER trial (11).
he PROSPER trial recruited patients 70 to 82 years of
ge with cardiovascular risk factors (primary prevention
ohort) or documented cardiovascular diseases (secondary
revention cohort). The results of this trial did not
uggest any discernible effect of statin therapy on all-
ause mortality. The published PROSPER trial did not
eport all-cause mortality results stratified by primary and
econdary prevention cohorts; however, the unpublished
ROSPER data obtained for this meta-analysis showed that
he secondary prevention cohort did derive a significant
enefit in all-cause mortality (Fig. 2). As may have been
xpected (35), the primary prevention cohort did not de-
ive a significant benefit and diluted the overall effect
stimate.
In addition to the modest results of the PROSPER trial
nd the heterogeneous odds ratios reported by meta-
nalyses, safety and cost concerns limit the use of statins in
lderly patients. Available evidence suggests that these
oncerns may be exaggerated. We did not pool adverse
vents and cost effectiveness because of failure to report
hese events stratified by age group in most studies and
nconsistencies in classification of these events between
tudies.
The LIPID study and the Cholesterol Reduction in
eniors Program showed that the incidence of hepatic,
uscular, dermatologic, respiratory, genitourinary, gastro-
ntestinal, and traumatic adverse events were similar in
atients 65 and 65 years of age (17,36). HPS and the
holesterol Treatment Trialists showed that the incidence
f nonvascular death from cancer or other causes was similar
n patients treated with statins or placebo (18,37). Two
eta-analyses focused on the effect of statins on cancer risk
oncluded that statins have a neutral effect on overall and
ite-specific cancer incidence and death (38,39). 4S and the
ravastatin Pooling Project showed that the rate of treat-
ent discontinuations because of any adverse event was
urprisingly increased in patients treated with placebo
15,40). The reason for this is unclear, but the authors pypothesized that placebo-treated patients suffered adverse
vents as a result of not taking statins. Furthermore, the
ROSPER trial showed that the effect of polypharmacy,
here patients were taking up to 16 concomitant drugs, did
ot negate the benefits of statins (41). One explanation may
e because pravastatin is not metabolized by cytochrome
450 and thus has low potential for drug–drug interactions.
n overview of statin safety and drug interactions (42), as
ell as meta-analyses of statin-related adverse events, have
een previously published (43,44).
The cost-effectiveness ratio of statins was shown to be
18,800 per quality-adjusted life-year in patients aged 75 to
4 years (45–47) (comparable to the cost of commonly
ccepted treatments such as treating hypertension in adults
ges 35 to 64 years). Like the number needed to treat, the
ost-effectiveness ratio is a function of baseline risk. There-
ore, the cost-effectiveness ratio is favorable in the elderly
atient population because they have a higher risk of
ortality and morbidity.
Women represented one-quarter of patients in our elderly
ubgroups, which is greater than the proportion in the
onelderly subgroups but less than the true proportion in
he aging population. Although women continue to be
nder-represented in clinical trials, it is reassuring to note
hat gender was not a significant effect modifier in these
CTs. The magnitude of the relative risk reduction for
ortality or major morbidity was similar in men and women
confidence intervals sometimes crossed unity in women as
result of insufficient sample size and power).
Our study has several potential limitations. First, sub-
roup analyses must be interpreted cautiously because of
ailure to account for multiple hypotheses and, as a result, a
isk of finding spurious subgroup effects (48). We believe
hat this risk is minimal in our meta-analysis because we
nalyzed similar subgroups across independent RCTs and
id not observe qualitative differences. The majority of the
CTs stratified randomization by age group, further reduc-
ng the risk of unbalanced randomization. Second, we did
ot identify any placebo-controlled RCTs of secondary
revention for newer statins such as atorvastatin and rosu-
astatin. This issue is mitigated by a study that showed that
ifferent statins were equally effective (class effect) for
econdary prevention of CHD in elderly patients (49).
astly, we were unable to obtain elderly-patient data from 7
CTs. It is unlikely that these RCTs would change our
esults, because their respective patient characteristics and
verall results were similar to the included RCTs and their
ample sizes were relatively small. Moreover, we were able
o obtain unpublished data from several sources. Published
rials tend to favor the intervention, and meta-analyses
estricted to published trials tend to overrepresent the actual
ffect (publication bias). To our knowledge, no other meta-
nalysis has reported unpublished data for the elderly
atient population.
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Statins for Secondary Prevention in Elderly Patients January 1/8, 2008:37–45onclusions
he use of statins for secondary prevention of cardiovascular
vents is commonly accepted in young and elderly patients.
ur meta-analysis adds to the current body of literature by
howing that statins reduce all-cause mortality in elderly
atients and that the magnitude of this effect is substantially
arger than previously estimated. In addition, statins reduce
onfatal major adverse cardiac events, which have been
hown to increase the risk of functional decline and perma-
ent disability in older adults (50,51), especially those who
re frail (52,53). Despite the fact that older patients derive
he most benefit at the lowest cost, old age is still an
ndependent risk factor for underutilization of statins (54).
here has been a global increase in statin utilization with
he emergence of RCT evidence in the past 5 years (55–57)
nd a few regional increases with the use of knowledge
ranslation programs and quality control initiatives (58–60).
owever, recently reported utilization rates of 40% to 60%
n elderly patients with active CHD remain suboptimal
5–8). It is crucial to disseminate the evidence for statins in
lderly patients with CHD to increase current utilization
ates.
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